4,5,6,7-四氢吡唑并[1,5-a]吡啶-2-甲酰氯 | 307313-04-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4,5,6,7-四氢吡唑并[1,5-a]吡啶-2-甲酰氯
• 英文名称: 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-2-carboxylic acid chloride
• 英文别名: 4,5,6,7-Tetrahydropyrazolo[1,5-a]pyridine-2-carbonyl chloride
• CAS: 307313-04-8
• 化学式: C₈H₉ClN₂O
• 分子量: 184.625
• InChiKey: ZCWLFUISVBQJOS-UHFFFAOYSA-N

物化性质

• 沸点：
  331.7±30.0 °C(Predicted)
• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,5-二氨基吡啶 、 4,5,6,7-四氢吡唑并[1,5-a]吡啶-2-甲酰氯 在 吡啶 作用下， 生成 N-(5-aminopyridin-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-2-carboxamide
  参考文献：
  名称：

  A novel series of metabotropic glutamate receptor 5 negative allosteric modulators based on a 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine core

  摘要：

  A series of potent non-acetylinic negative allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5 NAMs) was developed starting from HTS screening hit 1. Potency was improved via iterative SAR, and physicochemical properties were optimized to deliver orally bioavailable compounds acceptable for in vivo testing. A lead molecule from the series demonstrated dose-dependent activity in the second phase of the rat formalin test from 30 mg/kg, and a preliminary PK/PD relationship was established. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.044
• 作为产物：
  描述：

  methyl 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-2-carboxylate 在 甲醇 、 草酰氯 、 N,N-二甲基甲酰胺 、 potassium hydroxide 作用下， 以 二氯甲烷 为溶剂， 生成 4,5,6,7-四氢吡唑并[1,5-a]吡啶-2-甲酰氯
  参考文献：
  名称：

  A novel series of metabotropic glutamate receptor 5 negative allosteric modulators based on a 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine core

  摘要：

  A series of potent non-acetylinic negative allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5 NAMs) was developed starting from HTS screening hit 1. Potency was improved via iterative SAR, and physicochemical properties were optimized to deliver orally bioavailable compounds acceptable for in vivo testing. A lead molecule from the series demonstrated dose-dependent activity in the second phase of the rat formalin test from 30 mg/kg, and a preliminary PK/PD relationship was established. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.044

文献信息

• [DE] CARBOXAMIDE DES INDOLIZINS UND SEINER AZA- UND DIAZADERIVATE<br/>[EN] INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF<br/>[FR] CARBOXAMIDES D'INDOLIZINE ET LEURS AZA- ET DIAZA-DERIVES
  申请人：SANOL ARZNEI SCHWARZ GMBH

  公开号：WO2006015737A1

  公开（公告）日：2006-02-16

  Die vorliegende Erfindung betrifft neurorezeptoraktive Carboxamid-substituierte Indolizin­-Derivate der allgemeinen Formel (I) wobei X eine Gruppe mit der allgemeinen Formel (X1) repräsentiert.

  本发明涉及具有神经受体活性的羧酰胺取代的吲哩啉衍生物，其一般式为（I），其中X代表一种具有一般式（X1）的基团。